Breaks Categories: Analyst Alerts

FridaySep 08, 2017 11:59 am

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock. The analyst cites the company’s two glaucoma drugs as being well-positioned for FDA approvals, with Rhopressa anticipated for approval in the first half of 2018 and Roclatan expected to be approved in the first half of 2019. Given the strong efficacy and safety profiles of both drug candidates, the analyst believes it is likely they will both be approved. Additionally, the analyst believes that by the year 2025 the company could reach $239 million…

Continue Reading

ThursdaySep 07, 2017 12:01 pm

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on LongFin Corp. (NASDAQ: LFIN)

SeeThruEquity has initiated coverage and set a price target of $8.42 on shares of LongFin Corp.’s (Nasdaq pending, "LFIN") stock. LongFin is a non-banking Fintech company providing structured commodity trade finance (shadow banking) solutions and is currently pending listing on the Nasdaq Capital Market. Among other highlights, the analyst noted the company’s goal of connecting 70 FX and spot exchanges and more than 300 banks across the globe via its electronic market making (EMM) trading platform. The shadow banking industry was estimated at $34 trillion in 2015 and is expected to grow further as the global trade financing gap continues…

Continue Reading

WednesdayAug 30, 2017 1:14 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage, Increase PT on FTE Networks, Inc. (FTNW)

SeeThruEquity has updated its coverage and increased its price target to $3.20 on shares of FTE Networks, Inc.’s (OTCQX: FTNW) stock following the company’s recent report of financial results for the second quarter of 2017. FTE completed the acquisition of Benchmark Builders, Inc. in April, which contributed to its reported revenues of $50.2 million for the second quarter, a massive increase compared to $3.2 million for the same period of 2016. In addition to contributing to revenues, the company’s acquisition of Benchmark also expands its service capabilities and almost doubles its sales backlog. For more information, visit www.ftenet.com About FTE…

Continue Reading

TuesdayAug 29, 2017 11:47 am

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on Nexeon MedSystems, Inc. (NXNN)

SeeThruEquity has initiated coverage and a price target of $2.40 on shares of Nexeon MedSystems, Inc.’s (OTCQB: NXNN) stock. The analyst noted that there are several potential upcoming catalysts for Nexeon, such as the company’s capital raise in the form of issuing a $3 million private placement with price protection and 50% warrant coverage. Additionally, the company plans to commence commercial activities in the second quarter of 2018 for its lead product, NNS, a neurostimulation and recording platform for deep brain stimulation (DBS) that has previously received a CE Mark. The development stage medical device company believes NNS has the…

Continue Reading

FridayAug 25, 2017 11:25 am

NetworkNewsBreaks – SeeThruEquity Issues Update on Myomo, Inc. (NYSE: MYO)

SeeThruEquity has updated its coverage and maintained its price target of $9.35 on shares of Myomo, Inc.’s (NYSE: MYO) stock following the company’s recent report of financial results for the three and six months ended June 30, 2017. The analyst noted the company’s recent progress, such as the growth capital raise of $8 million as well as the newly-secured CE Mark approval for the commercial sale of its next generation MyoPro® myoelectric arm orthosis in Europe. Since receiving CE Mark approval, the company plans to target Europe, starting with Germany through its sales partnership with Ottobock. For more information, visit…

Continue Reading

TuesdayAug 22, 2017 12:03 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Innovus Pharmaceuticals, Inc. (INNV)

SeeThruEquity has updated its coverage and maintained its price target of $0.65 on shares of Innovus Pharmaceuticals, Inc.’s (OTCQB: INNV) stock following the company’s report of financial results for the second quarter of 2017. Revenues of $2 million were reported for the quarter, a 99% increase over the second quarter of 2016. The company also confirmed that the commercial launch of FlutiCare™ is set for the fourth quarter of 2017. For more information, visit www.innovuspharma.com About Innovus Pharmaceuticals, Inc. Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization,…

Continue Reading

WednesdayAug 16, 2017 9:56 am

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on PotNetwork Holding, Inc. (POTN)

SeeThruEquity has initiated coverage and issued a price target of $0.25 on shares of PotNetwork Holding, Inc.’s (OTC: POTN) stock. Among other highlights, the analyst noted the market potential for cannabidiol, such as the company’s Diamond CBD. PotNetwork reported Diamond CBD revenues of over $1 million in April 2017, a significant increase compared to revenues of $40,000 in April 2016. The company has also been showcasing its CBD oil and specialty products at numerous events this year, including some of the busiest gatherings in the industry, which reportedly resulted in more than 500 new accounts for the company. For more…

Continue Reading

TuesdayAug 15, 2017 2:13 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage, Increases PT on Medical Transcription Billing, Corp. (NASDAQ: MTBC)

SeeThruEquity has updated its coverage and increased its price target to $4 on shares of Medical Transcription Billing, Corp.’s (NASDAQ: MTBC) stock. The company recently reported financial results for the second quarter of 2017, including a 49% increase in revenues, year-over-year. MTBC also reported a 55% increase for the first half of 2017, with revenues of approximately $16 million. The company attributes this growth primarily to its largest acquisition, MediGain, and a higher rate of retention from MediGain customers than originally expected. For more information, visit www.mtbc.com About Medical Transcription Billing, Corp. MTBC is a healthcare information technology company that…

Continue Reading

ThursdayAug 10, 2017 9:46 am

NetworkNewsBreaks – SeeThruEquity Issues Update, New PT on IEG Holdings Corp. (IEGH)

SeeThruEquity has updated its coverage and issued a new price target of $5.20 on shares of IEG Holdings Corp.’s (OTCQB: IEGH) stock following the company’s recent release of financial results for the second quarter of 2017. Among other highlights, the analyst noted that the results showed a decrease in operating costs as well as an improved balance sheet for IEG. Additionally, the company declared a cash dividend of $0.005 per common share for the second quarter of 2017. The dividend is payable on August 21, 2017, to stockholders of record at the close of business on Friday, August 11, 2017.…

Continue Reading

ThursdayAug 03, 2017 12:12 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Earth Science Tech, Inc. (ETST)

SeeThruEquity has updated its coverage and issued a price target of $4.12 on shares of Earth Science Tech, Inc.’s (OTC: ETST) stock. Among other highlights, the analyst noted the company’s new joint venture with Varsity Group, LLC to use its patented Kanna-Blend formula to develop CBD-based e-liquids to be sold under ETST's subsidiary, KannaBidoid Inc. The company has already finalized four product labels for it e-liquids that will start selling by the end of August 2017. Additionally, ETST has inked an agreement with Absolu Communications to handle the branding and rollout of the company’s much-anticipated MSN-2 medical device. For more…

Continue Reading